# A Phase II Study of Sintilimab Combined With Anlotinib in Treatment of ED-SCLC

> **NCT04967625** · PHASE2 · UNKNOWN · sponsor: **Zhejiang Cancer Hospital** · enrollment: 23 (estimated)

## Conditions studied

- Small Cell Lung Cancer Extensive Stage

## Interventions

- **DRUG:** Sintilimab
- **DRUG:** Anlotinib hydrochloride

## Key facts

- **NCT ID:** NCT04967625
- **Lead sponsor:** Zhejiang Cancer Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-07-26
- **Primary completion:** 2022-12-31
- **Final completion:** 2023-12-31
- **Target enrollment:** 23 (ESTIMATED)
- **Last updated:** 2021-07-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04967625

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04967625, "A Phase II Study of Sintilimab Combined With Anlotinib in Treatment of ED-SCLC". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT04967625. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*